Dr Levy on the Ongoing Development of TROP-2 ADCs in NSCLC

Benjamin Philip Levy, MD, discusses the ongoing development of the TROP-2 directed antibody-drug conjugates sacituzumab govitecan-hziy and datopotamab deruxtecan in non–small cell lung cancer, their different toxicity profiles, as well as the potential categorization of emerging ADCs as onco-directed therapies in this patient population.

Related Keywords

,Johns Hopkins Sidney Kimmel Cancer Center ,Johns Hopkins University School Of Medicine ,Benjamin Philip Levy ,Johns Hopkins University School ,Medical Oncology ,Sibley Memorial Hospital ,D ,Patients With Non Small Cell Lung Cancer ,Johns Hopkins Sidney Kimmel Cancer Center At Sibley Memorial Hospital ,Trop 2 Adcs ,